Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Carlsmed (NASDAQ:CARL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.
Earnings & Valuation
This table compares Vivos Therapeutics and Carlsmed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.11 | -$21.17 million | ($1.90) | -0.05 |
| Carlsmed | $50.51 million | 9.13 | -$29.63 million | ($1.48) | -11.38 |
Vivos Therapeutics has higher earnings, but lower revenue than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vivos Therapeutics and Carlsmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Carlsmed | -55.82% | -42.42% | -30.87% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Vivos Therapeutics and Carlsmed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Carlsmed | 1 | 1 | 4 | 0 | 2.50 |
Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 2,862.96%. Carlsmed has a consensus price target of $22.00, indicating a potential upside of 30.65%. Given Vivos Therapeutics’ higher possible upside, equities analysts plainly believe Vivos Therapeutics is more favorable than Carlsmed.
Insider & Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. 1.4% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Carlsmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Vivos Therapeutics has a beta of 6.37, indicating that its stock price is 537% more volatile than the S&P 500. Comparatively, Carlsmed has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.
Summary
Carlsmed beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
About Carlsmed
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
